000			02119 a2200553 4500
005			20250515121805.0
264		0	_c20080918
008			200809s 0 0 eng d
022			_a1744-7658
024	7		_a10.1517/13543784.17.6.845 _2doi
040			_aNLM _beng _cNLM
100	1		_aMikhail, Nasser
245	0	0	_aIncretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. _h[electronic resource]
260			_bExpert opinion on investigational drugs _cJun 2008
300			_a845-53 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAdamantane _xadverse effects
650	0	4	_aBody Weight _xdrug effects
650	0	4	_aClinical Trials, Phase III as Topic _xstatistics & numerical data
650	0	4	_aDiabetes Mellitus, Type 2 _xblood
650	0	4	_aDipeptidyl Peptidase 4
650	0	4	_aDipeptidyl-Peptidase IV Inhibitors _xadverse effects
650	0	4	_aDouble-Blind Method
650	0	4	_aDrug Therapy, Combination
650	0	4	_aExenatide
650	0	4	_aGlucagon-Like Peptide 1 _xpharmacokinetics
650	0	4	_aGlucagon-Like Peptide-1 Receptor
650	0	4	_aGlycated Hemoglobin _xanalysis
650	0	4	_aHumans
650	0	4	_aHypoglycemia _xchemically induced
650	0	4	_aHypoglycemic Agents _xadverse effects
650	0	4	_aIncretins _xphysiology
650	0	4	_aInsulin _xmetabolism
650	0	4	_aInsulin Secretion
650	0	4	_aNausea _xchemically induced
650	0	4	_aNitriles _xadverse effects
650	0	4	_aPeptides _xadverse effects
650	0	4	_aPyrazines _xadverse effects
650	0	4	_aPyrrolidines _xadverse effects
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aReceptors, Glucagon _xdrug effects
650	0	4	_aSitagliptin Phosphate
650	0	4	_aTriazoles _xadverse effects
650	0	4	_aVenoms _xadverse effects
650	0	4	_aVildagliptin
650	0	4	_aVomiting _xchemically induced
773	0		_tExpert opinion on investigational drugs _gvol. 17 _gno. 6 _gp. 845-53
856	4	0	_uhttps://doi.org/10.1517/13543784.17.6.845 _zAvailable from publisher's website
999			_c17986148 _d17986148